Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma.

Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma.
Clin Chim Acta. 2018 Feb 19;:
Authors: Pan Y, Chen H, Shen X, Wang X, Ju S, Lu M, Cong H
Abstract
Circulating long noncoding RNA (lncRNA) H19 has been reported to be a biomarker for cancer monitoring. The purpose of this study was to determine whether serum lncRNA could serve as a novel biomarker for the diagnosis of multiple myeloma (MM) and evaluate its value of clinical application. In our study, the expression of lncRNA H19 was up-regulated in 80 patients with MM and MM cell lines by RT-PCR analysis. Clinicopathological analysis showed the expression level of H19 could assist clinical staging, and the severity of the disease could be roughly determined according to the amount of H19 expressed in the patient serum. This is the first report to show that H19 was expressed in the serum of MM patients, suggesting that upregulation of serum lncRNA H19 may prove to be a novel biomarker for early diagnosis and clinical treatment of MM.
PMID: 29470951 [PubMed - as supplied by publisher]

Source: International Journal of Clinical Chemistry - February 19, 2018 Category: Chemistry Authors: Pan Y, Chen H, Shen X, Wang X, Ju S, Lu M, Cong H Tags: Clin Chim Acta Source Type: research